Please use this identifier to cite or link to this item:
|Title:||Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning||Authors:||Coutsouvelis, John
Kirkpatrick, Carl M
|Issue Date:||2022||Publisher:||Nature Publishing Group||Source:||Coutsouvelis J, Dooley M, Kirkpatrick CM, Avery S, Hopkins R, Spencer A. Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning. Bone Marrow Transplant. 2022 May 19. doi: 10.1038/s41409-022-01714-6. Epub ahead of print. PMID: 35589999.||Journal:||Bone marrow transplantation||Description:||Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Sharon Avery||DOI:||10.1038/s41409-022-01714-6||Type:||Article|
|Appears in Sites:||Cairns & Hinterland HHS Publications|
Show full item record
checked on Dec 10, 2022
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.